最新消息 >首頁>最新消息>【公告】2019多體學及精準醫學聯合會議 海報展演名單與口頭報告名單
【公告】2019多體學及精準醫學聯合會議 海報展演名單與口頭報告名單
本公告附加檔案:  
 

2019/11/29

2019多體學及精準醫學聯合會議 

詳情請見大會官網

口頭報告名單:

※每位講員依報告順序依序進行口頭報告,時間各13分鐘(10分鐘口頭報告,3分鐘發問問題)
OC-01
王庭
Combination Therapy with Dendritic Cell Vaccine and PD-L1 Immune Checkpoint Inhibitor for Hepatocellular Carcinoma in An Orthotopic Mouse Model
OC-02
翁靖傑
Loss of the Transcriptional Repressor TGIF1 Results in Enhanced Kras-Driven Development of Pancreatic Cancer
OC-03
石一㚬
A Turn-on Fluorescence Sensor for Heparin Detection Based on a Release of Taiwan Cobra Cardiotoxin from a DNA Aptamer or Adenosine-Based Molecular Beacon
OC-04
鄭以安
Non-covalent modification of mPEGylated nanoparticles by humanized bispecific antibodies for selective therapy
OC-05
王亮鈞
VINCRISTINE INDUCES APOPTOSIS OF HUMAN LEUKEMIA U937 CELLS VIA SIRT3/ROS/p38 MAPK/TTP AXIS-MEDIATED TNF-α UPREGULATION
OC-06
呂韻綺
Specific activation of a pro-Remicade can enhance the selectivity and safety of rheumatoid arthritis therapy

海報展演名單:
C1-01
黃信凱
Investigation of influence of microbiota on colorectal cancer patients using Irinotecan (CPT-11) induced diarrhea
C2-01
吳怡萱
Development of the protease-activated pro-Humira to prevent the interfere effect of neutralizing anti-idiotype antibody
C2-02
李子瑜
Development of pro-immune checkpoint antibody to increase selectivity and reduce side effects
C2-03
吳亭儀
Non-covalent Modified mPEGylated Nanodrugs with Anti-PEG Bispecific Antibody(αmPEGxαCD20) to Enhance Tumor Specific Targeting and Therapeutic Efficacy in Lymphoma
C2-04
黃怡嘉
To compare the immunogenicity of pro-antibody that mask antibody-binding sites with hinge domain or coiled-coil domain in mice model
C4-01
劉建均
Screening of DNA aptamers toward oral cancer biomarkers using plate-based SELEX and next-generation sequencing
C4-02
葉宏淳
Butanolide compounds from Cinnamomum kotoense induce melanoma autophagy and apoptosis via MAPK pathway in vivo and in vitro
C4-03
詹雅玲
Human T-cell lymphoma invasion and metastasis 2 promotes chronic inflammation mediated tumorigenicity
C4-04
傅曉婷
The survival time of non-small cell lung cancer patients conducted with different treatments, alone or in combination: A single center study.
C4-05
林宜玫
The relationship of serotonin receptor 1A polymorphisms with woman menopause symptom and pro-inflammatory cytokines
C4-06
張培均
Inhibition Assessment of Anticancer Drugs for ALK Gene Variation Target
C4-07
王怡絜
O-Methyleugenol from Cinnamomum subavenium Enhance Doxorubicin Chemotherapy Efficacy to Inhibit Human Lung Cancer Cell Proliferation and Reverse Epithelial-to-Mesenchymal Transition Pathway
C4-08
吳秉璁
Development of a humanized bi-specific antibody (αEphA2×α-mPEG) for specific targeting and endocytosis of glycosidic switch liposomes to EphA2-expressing metastatic tumors
C4-09
黃佳慧
ARSENIC TRIOXIDE INDUCES APOPTOSIS IN BCR-ABL1-POSITIVE LEUKEMIA CELLS VIA P38 MAPK-AND AKT-MEDIATED MCL1 DOWNREGULATION
C4-10
李苑親
EGFR-Mediated AGO2 Phosphorylation Upregulates MCL1 Expression in ABT-263-treated Human Leukemia Cells
C4-11
邱靖婷
AUTOPHAGIC DEGRADATION OF HUR ELICITS DOWNREGULATION OF SURVIVIN AND MCL1 IN YM-155-TREATED HUMAN LEUKEMIA K562 CELLS
C4-12
黃奕中
Tet-on the expression of ERCC1 increase radioresistance of colorectal cancer in vivo
C4-13
萬郁瑩
Extract Capsicum annuum chemical composition and enhance chemodrug inhibition lung cancer growth
C4-14
謝雅茹
The Roles of GSKIP in Metastatic Ability and Radioresistance of Oral Squamous Cell Carcinoma
C4-15
黃柏誠
Development of protease-activated pro-antibody by structure-based computational methods
C4-16
陳慧蓁
An autologous hinge as universal antibody lock enhances selectivity of antibody whilst prevent the binding of anti-idiotype antibody
C4-17
李安倫
The microRNA classifiers as ancillary diagnosis biomarkers for urothelial carcinoma of chronic kidney disease
C4-18
吳佩珊
Development of protease-activated pro-anti-CTLA4 antibody to enhance disease selectivity and reduce the side effects
C4-19
李承恩
To investigate the importance of disulfide bond to spatial-hindrance-based pro-antibody
C4-20
李佳靜
One-step Mixing of Anti-mPEG Bispecific Antibody (mPEG×HER2) with PEGylated Nanoparticles to Enhance Its Therapeutic Efficacy in Ovarian Cancer
C4-21
蔡婉琪
Compound X from Ardisia virens inhibits tumorigenesis and metastatic potential in pancreatic cancer
C4-22
全鄧雅文
Effect of fucoidan from Fucus vesiculosus on lung adenocarcinoma cells resistance to chemotherapeutic drug doxorubicin
C4-23
王碩鴻
To develop a protease inhibitor for Zika virus therapy
C4-24
柯建志
Radiation-modulated prostate cancer derived-exosomes regulates the epithelial-mesenchymal transition of recipient cells
C4-25
廖子毅
Bispecific antibody (CD20 Ab × mPEG scFv) specific targets liquid tumors to enhance anti-tumor efficacy by actively grab PEGylated liposomal doxorubicin 
C4-26
趙郁舒
Leader compounds provide less cytotoxicity and higher specificity to inhibit type I~IV Dengue
C4-27
陳怡如
Developing Bispecific Antibody for Synergistic Anti-Cancer Effects by Precise Targeting and Accumulation of PEGylated Drugs
C4-28
洪詩婷
Correlation of anti-PEG antibody with the therapeutic efficacy of Mircera
C4-29
劉蕙如
Targeted mPEG-nanoparticle Release into Blood-Brain Barrier by a Protease Cleavable BsAb (mPEG×TfR)

口頭論文,海報發表規則

規則:
  1. 每篇至少請一位作者完成報名及註冊繳費程序。
  2. Oral presentation 報告議程及順序請參考「投稿結果公告」頁面。
  3. poster論文議程、海報編號請參考公告。
  4. 12/7 13:00~14:00由編號單數號報告;12/8 13:00~14:00由編號雙數號報告。
口頭論文發表規則:
  1. 口頭發表時間 : 12/8 14:00-15:30
  2. 報告者務必於開始前三十分鐘到達,並將報告之投影片(以Power Point製作並存放於隨身碟),交付現場服務人員存放於該場次電腦中。
  3. 現場備有電腦(附有 USB 插槽)、單槍投影機、簡報筆及麥克風,如有其他發表設備需求,請事先與工作人員接洽。
  4. 每個人口頭報告時間為 13 分鐘(包含口頭報告 10 分鐘與提問時間 3 分鐘)。
  5. 口頭報告10分鐘內,將會再在第 8、9與第 10 分鐘時,各響鈴提示一次,共計三次,提醒報告人掌握時間;提問時間內,第12分鐘響鈴提示倒數1分鐘,第13分鐘響鈴結束討論。
  6. 優秀論文獎:
    (1)由各學會敦聘專家評審進行評選。
    (2)獎勵方式:於閉幕典禮頒獎。
海報論文發表規則:
  1. 報到完畢後,請找到自己的海報編號板進行張貼,海報編號請參考「投稿結果公告」。
  2. 海報張貼最慢需於發表前10分鐘完成,並在指定地點張貼完畢,會場備有張貼海報之文具供發表者使用。
  3. 請發表人於海報發表時段在張貼地點就位,以回答評審及提問者之問題,如不在場將不頒發證書及取消優秀論文獲獎資格。
  4. 各海報發表場次時段如下所示:
    (1)論文海報 I 場次發表者(單數號)請於12月7日(六) 13:00~14:00就位
    (2)論文海報 II 場次發表者(雙數號)請於12月8日(日) 13:00~14:00就位
  5. 優秀論文獎:
    (1)由各領域的評審進行評選。
    (2)獎勵方式:入選優秀論文者,大會將於閉幕典禮頒獎。
 
回上頁

+電話 /  07-3121101分機2697,2733 +傳真 / -    
+地址 / 807高雄市三民區十全一路100號     +E-mail / tgmbs.so@gmail.com
Copyright 2010 © 台灣基因醫學暨生物標記學會 All Right Reserved. Designed │